Navigation Links
Edison highlights the potential of GW Pharmaceuticals' cannabinoid pipeline and furthers its US healthcare presence
Date:12/10/2013

LONDON, Dec. 10, 2013 /PRNewswire/ -- Edison's ADR outlook note, Orphan opportunities, highlights that 2014 could be transformative for GW as its pipeline delivers important clinical milestones. GW's acceleration of orphan programmes in childhood epilepsy (Epidiolex) and primary brain cancer (THC:CBD combination) should generate clinical data and Phase II starts for both indications. In addition, the company's lead programme, Sativex, is approaching key value inflection points including Phase III cancer pain data (Q414) and the US Phase III start in MS spasticity (H214).

Edison's healthcare team forecasts peak sales for Epidiolex in Dravet syndrome (DS) of $288m, THC/CBD (GBM) of $246m and GWP42004 (type 2 diabetes) of $1,025m. It projects Sativex peak sales potential of $814m – MS Spasticity at $278m (US $176m, ex-US $102m) and cancer pain at $536m (US $350m, ex-US $186m).

Edison's revised DCF valuation is $715m, or $48.30 per ADR, following the inclusion of R&D pipeline programmes. Positive data from physician-led studies of Epidiolex (mid-2014 onwards) would see the DCF rise to $818m or $55.30/ADR. Positive Sativex Phase III data in cancer pain (late 2014) would see the DCF rise further to $867m or $58.60/ADR. GW's remaining R&D programmes (epilepsy, ulcerative colitis and schizophrenia) offer pure upside to Edison's valuation.

For the full report see: www.edisoninvestmentresearch.com/research/company/GW-Pharmaceuticals

About Edison Investment Research This continued ADR coverage on GW Pharmaceuticals is part of a programme of research coverage on pharmaceutical companies exposed to global market opportunities. Edison provides detailed research on more than 150 pharmaceutical and healthcare companies in Europe, North America, '/>"/>

SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
2. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
9. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
10. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
11. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Fla. , Aug. 1, 2014 Dyadic ... whose patented and proprietary technologies are used to develop, ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... the second quarter ended June 30, 2014 after market ... a conference call that day at 5:00 p.m. Eastern ...
(Date:7/31/2014)... , July 31, 2014  According to data released ... the 2015 average monthly Medicare Part D premium is ... lower than was originally projected, the Pharmaceutical Care Management ... program continues to be a bright spot in American ... in each region and using cutting edge, cost-saving tools ...
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... ALLEGAN, Mich., May 10, 2011 Perrigo Company (Nasdaq: ... to settle all Hatch-Waxman litigation relating to fluticasone lotion brought ... relevant patents. Under the terms of the settlement, Perrigo can ... 22, 2012, or earlier under certain circumstances. ...
... Tenn., May 10, 2011 MedQuist Holdings Inc. (NASDAQ: ... transcription services and technology-enabled clinical documentation workflow solutions, today ... St. Joseph,s Hospital Health Center in Syracuse, New York, ... projected to achieve significant cost savings and improve efficiency ...
Cached Medicine Technology:Perrigo Announces Settlement of Cutivate Lotion Litigation 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 3
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... NV (PRWEB) August 01, 2014 ... opportunities for independent community pharmacies. At ThoughtSpot 2014, ... are equipped with practices and resources to enhance ... AmerisourceBergen leaders focused on critical issues to give ... optimize and grow. , ThoughtSpot show attendance ...
(Date:8/1/2014)... Dallas, Texas (PRWEB) August 01, 2014 ... universal health coverage and healthcare reforms are boosting ... price of medicines through discounts and increasing generic ... stood at approximately 76.7 million in 2013, having ... of 1.4%, from 2008. The implementation of the ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... importance of a nutritious lunch towards maintaining a healthy ... Commonwealth Games gold medal marathon runner// and mother of ... Dr John Tickell, and award-winning chef Michael Moore. ... to encourage Australians to make a healthy lunch a ...
... which are mainly used to prevent blocking of various arteries ... patients require other procedures// such as angioplasty or a by ... flexible nickel-titanium tubes. They are very effective in ... Researchers conducted a new study and published it in the ...
... that they are requesting patients to take a blood ... for a blood test for HIV and Hepatitis. Scripps ... nurse had failed to follow proper sterilization procedures for ... the so-called stomach-stapling operations. The instrument requires a different ...
... look into the costs of healthcare, met in Adelaide, and ... extremely high and has no system of prioritising patients. ... reason for wanting her breasts reduced has to wait just ... aesthetic reasons. Women who were in need for the surgery ...
... meet this week in Abuja, Nigeria, to review the progress ... malaria, tuberculosis. ,Five years ago the leaders had ... 15 per cent of national budgets in order to accelerate ... as other diseases. ,However progress has been dismal. ...
... carry a potential risk of suffering asthma, than compared to ... is published in the May 1 issue of Environmental Health ... 75 meters (about 82 yards) of a major road had ... in the past year than were children who lived more ...
Cached Medicine News:Health News:Celebrities Promote Healthy Lunch 2Health News:Waiting Period Of Over 10yrs For Women Needing Breast Reduction Surgery 2Health News:Review of Reversal of Spread of Diseases in Africa 2Health News:Asthma Risk Pronounced In Children Living Close to Traffic Ridden Roads 2
... EasyID is a patient identification ... cost savings by eliminating embossers, imprinters ... efficiency and workflow throughout the facility. ... patient identification and is designed to ...
The Metrologic MS9520 Voyager is a high performance single line laser bar code scanner with automatic activation and sophisticated data transmission via Metrologic proprietary CodeGate technology....
... latex-free, thermal transfer wristband for printing ... images that resist smears and abrasion ... cleaners, and blood. A time-tested and ... patron management applications. A tamper-evident VOID ...
... Durable, secure, direct thermal wristband ... entertainment venue patron admissions. Its clip ... five colors plus white for color ... Zebra printers for peak performance. Print ...
Medicine Products: